Erectile dysfunction is a multidimensional but common male sexual dysfunction that involves an alteration in any of the components of the erectile response, including organic, relational and psychological. Roles for nonendocrine (neurogenic, vasculogenic and iatrogenic) and endocrine pathways have been proposed. Owing to its strong association with metabolic syndrome and cardiovascular disease, cardiac assessment may be warranted in men with symptoms of erectile dysfunction. Minimally invasive interventions to relieve the symptoms of erectile dysfunction include lifestyle modifications, oral drugs, injected vasodilator agents and vacuum erection devices. Surgical therapies are reserved for the subset of patients who have contraindications to these nonsurgical interventions, those who experience adverse effects from (or are refractory to) medical therapy and those who also have penile fibrosis or penile vascular insufficiency. Erectile dysfunction can have deleterious effects on a man's quality of life; most patients have symptoms of depression and anxiety related to sexual performance. These symptoms, in turn, affect his partner's sexual experience and the couple's quality of life. This Primer highlights numerous aspects of erectile dysfunction, summarizes new treatment targets and ongoing preclinical studies that evaluate new pharmacotherapies, and covers the topic of regenerative medicine, which represents the future of sexual medicine.
Subscribe to Journal
Get full journal access for 1 year
only $59.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Virag, R., Zwang, G., Dermange, H. & Legman, M. Vasculogenic impotence: a review of 92 cases with 54 surgical operations. Vasc. Surg. 15, 9–17 (1981).
Glina, S., Shindel, A., Eardley, I. & Ghanem, H. Cavernosal α-blockade: a new technique for investigating and treating erectile impotence by GS Brindley. J. Sex. Med. 5, 1791–1794 (2008).
Scott, F. B., Bradley, W. E. & Timm, G. W. Management of erectile impotence. Use of implantable inflatable prosthesis. Urology 2, 80–82 (1973).
Blumenthal, S. A. Earl Sutherland (1915–1974) [corrected] and the discovery of cyclic AMP. Perspect. Biol. Med. 55, 236–249 (2012).
Ballard, S. A. et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol. 159, 2164–2171 (1998).
Gandaglia, G. et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur. Urol. 65, 968–978 (2014).
Feldman, H. A., Goldstein, I., Hatzichristou, D. G., Krane, R. J. & McKinlay, J. B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol. 151, 54–61 (1994). This seminal manuscript defines the prevalence of erectile dysfunction.
Corona, G. et al. Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J. Sex. Med. 7, 1362–1380 (2010).
Rosen, R. et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur. Urol. 44, 637–649 (2003). This publication describes the relationship of LUTS and erectile dysfunction.
Nicolosi, A. et al. Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology 64, 991–997 (2004).
Laumann, E. O. et al. Sexual problems among women and men aged 40–80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int. J. Impot. Res. 17, 39–57 (2005). An international study evaluating different aspect of sexual difficulties and some associated predictors.
Shabsigh, R., Perelman, M. A., Lockhart, D. C., Lue, T. F. & Broderick, G. A. Health issues of men: prevalence and correlates of erectile dysfunction. J. Urol. 174, 662–667 (2005).
Johannes, C. B. et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J. Urol. 163, 460–463 (2000).
Moreira, E. D. et al. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology 61, 431–436 (2003).
Schouten, B. W. et al. Incidence rates of erectile dysfunction in the Dutch general population. Effects of definition, clinical relevance and duration of follow-up in the Krimpen study. Int. J. Impot. Res. 17, 58–62 (2005).
Seftel, A. D. et al. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int. J. Clin. Pract. 67, 32–45 (2013).
Gacci, M. et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur. Urol. 60, 809–825 (2011).
Corona, G., Rastrelli, G., Maseroli, E., Forti, G. & Maggi, M. Sexual function of the ageing male. Best Pract. Res. Clin. Endocrinol. Metab. 27, 581–601 (2013).
Jannini, E. A. et al. Health-related characteristics and unmet needs of men with erectile dysfunction: a survey in five European countries. J. Sex. Med. 11, 40–50 (2014).
Ludwig, W. & Phillips, M. Organic causes of erectile dysfunction in men under 40. Urol. Int. 92, 1–6 (2014).
Capogrosso, P. et al. One patient out of four with newly diagnosed erectile dysfunction is a young man — worrisome picture from the everyday clinical practice. J. Sex. Med. 10, 1833–1841 (2013).
Heruti, R., Shochat, T., Tekes-Manova, D., Ashkenazi, I. & Justo, D. Prevalence of erectile dysfunction among young adults: results of a large-scale survey. J. Sex. Med. 1, 284–291 (2004).
Sanders, S. A. et al. General erectile functioning among young, heterosexual men who do and do not report condom-associated erection problems (CAEP). J. Sex. Med. 12, 1897–1904 (2015).
Papagiannopoulos, D., Khare, N. & Nehra, A. Evaluation of young men with organic erectile dysfunction. Asian J. Androl. 17, 11–16 (2015).
Yao, F. et al. Erectile dysfunction may be the first clinical sign of insulin resistance and endothelial dysfunction in young men. Clin. Res. Cardiol. 102, 645–651 (2013).
Salonia, A. et al. Is erectile dysfunction a reliable proxy of general male health status? The case for the International Index of Erectile Function–Erectile Function domain. J. Sex. Med. 9, 2708–2715 (2012).
Andersson, K. E. & Wagner, G. Physiology of penile erection. Physiol. Rev. 75, 191–236 (1995).
Saenz de Tejada, I., Kim, N., Lagan, I., Krane, R. J. & Goldstein, I. Regulation of adrenergic activity in penile corpus cavernosum. J. Urol. 142, 1117–1121 (1989). A seminal paper on cell signalling in the corpora cavernosum.
Lue, T. F. Erectile dysfunction. N. Engl. J. Med. 342, 1802–1813 (2000).
Lue, T. F. & Tanagho, E. A. Physiology of erection and pharmacological management of impotence. J. Urol. 137, 829–836 (1987).
McCabe, M. P. & Althof, S. E. A systematic review of the psychosocial outcomes associated with erectile dysfunction: does the impact of erectile dysfunction extend beyond a man's inability to have sex? J. Sex. Med. 11, 347–363 (2014).
Brackett, N. L., Lynne, C. M., Ibrahim, E., Ohl, D. A. & Sonksen, J. Treatment of infertility in men with spinal cord injury. Nat. Rev. Urol. 7, 162–172 (2010).
Leungwattanakij, S. et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J. Androl. 24, 239–245 (2003).
Ferrini, M. G. et al. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology 68, 429–435 (2006).
Ferrini, M. G., Kovanecz, I., Nolazco, G., Rajfer, J. & Gonzalez-Cadavid, N. F. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int. 97, 625–633 (2006).
Ferrini, M. G. et al. Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (CVOD) induced by experimental cavernosal nerve damage in the rat. J. Sex. Med. 6, 415–428 (2009).
Mulhall, J. P. et al. The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate. J. Sex. Med. 5, 1126–1136 (2008). This manuscript describes the science behind the use of sildenafil to decrease erectile tissue damage after cavernous nerve injury.
Kupelian, V., Araujo, A. B., Chiu, G. R., Rosen, R. C. & McKinlay, J. B. Relative contributions of modifiable risk factors to erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. Prev. Med. 50, 19–25 (2010).
Bacon, C. G. et al. A prospective study of risk factors for erectile dysfunction. J. Urol. 176, 217–221 (2006).
Francis, M. E., Kusek, J. W., Nyberg, L. M. & Eggers, P. W. The contribution of common medical conditions and drug exposures to erectile dysfunction in adult males. J. Urol. 178, 591–596 (2007).
Wei, M. et al. Total cholesterol and high-density lipoprotein cholesterol as important predictors of erectile dysfunction. Am. J. Epidemiol. 140, 930–937 (1994).
McVary, K. T., Carrier, S., Wessells, H. & Subcommittee on Smoking and Erectile Dysfunction Socioeconomic Committee, Sexual Medicine Society of North America. Smoking and erectile dysfunction: evidence based analysis. J. Urol. 166, 1624–1632 (2001). This publication examines the negative effects of smoking on erectile dysfunction.
Moreland, R. B. et al. PGE1 suppresses the induction of collagen synthesis by transforming growth factor-β 1 in human corpus cavernosum smooth muscle. J. Urol. 153, 826–834 (1995).
Moreland, R. B. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int. J. Impot. Res. 10, 113–120 (1998).
Nehra, A. et al. Mechanisms of venous leakage: a prospective clinicopathological correlation of corporeal function and structure. J. Urol. 156, 1320–1329 (1996).
Tal, R. et al. Persistent erectile dysfunction following radical prostatectomy: the association between nerve-sparing status and the prevalence and chronology of venous leak. J. Sex. Med. 6, 2813–2819 (2009).
Grimm, R. H. Jr et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 29, 8–14 (1997).
Baskin, L. S. et al. The effect of testosterone on androgen receptors and human penile growth. J. Urol. 158, 1113–1118 (1997).
Boas, M. et al. Postnatal penile length and growth rate correlate to serum testosterone levels: a longitudinal study of 1962 normal boys. Eur. J. Endocrinol. 154, 125–129 (2006).
Filippi, S. et al. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J. Sex. Med. 6, 3274–3288 (2009).
Vignozzi, L. et al. Testosterone regulates RhoA/Rho-kinase signaling in two distinct animal models of chemical diabetes. J. Sex. Med. 4, 620–630 (2007).
Hull, E. M. et al. Hormone–neurotransmitter interactions in the control of sexual behavior. Behav. Brain Res. 105, 105–116 (1999).
Isidori, A. M. et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment — a systematic review. Eur. Urol. 65, 99–112 (2014).
Mills, T. M., Lewis, R. W. & Stopper, V. S. Androgenic maintenance of inflow and veno-occlusion during erection in the rat. Biol. Reprod. 59, 1413–1418 (1998).
Lugg, J., Ng, C., Rajfer, J. & Gonzalez-Cadavid, N. Cavernosal nerve stimulation in the rat reverses castration-induced decrease in penile NOS activity. Am. J. Physiol. 271, E354–E361 (1996).
Giuliano, F., Rampin, O., Schirar, A., Jardin, A. & Rousseau, J. P. Autonomic control of penile erection: modulation by testosterone in the rat. J. Neuroendocrinol. 5, 677–683 (1993).
Traish, A. M. et al. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 140, 1861–1868 (1999).
Reilly, C. M., Lewis, R. W., Stopper, V. S. & Mills, T. M. Androgenic maintenance of the rat erectile response via a non-nitric-oxide-dependent pathway. J. Androl. 18, 588–594 (1997).
Sopko, N. A., Hannan, J. L. & Bivalacqua, T. J. Understanding and targeting the Rho kinase pathway in erectile dysfunction. Nat. Rev. Urol. 11, 622–628 (2014).
Liao, W., Huang, W., Guo, Y., Xin, M. & Fu, X. Testosterone promotes vascular endothelial cell migration via upregulation of ROCK-2/moesin cascade. Mol. Biol. Rep. 40, 6729–6735 (2013).
Zhang, X. H., Melman, A. & Disanto, M. E. Update on corpus cavernosum smooth muscle contractile pathways in erectile function: a role for testosterone? J. Sex. Med. 8, 1865–1879 (2011).
di Villa, B. R. et al. Sphingosine 1-phosphate induces endothelial nitric-oxide synthase activation through phosphorylation in human corpus cavernosum. J. Pharmacol. Exp. Ther. 316, 703–708 (2006).
Ohmori, T. et al. Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. Cardiovasc. Res. 58, 170–177 (2003).
Morelli, A. et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 145, 2253–2263 (2004).
Zhang, X. H. et al. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur. Urol. 47, 409–416 (2005). This manuscript describes the animal model showing the effect of testosterone on cavernosal tissue.
Yang, R. et al. Lack of direct androgen regulation of PDE5 expression. Biochem. Biophys. Res. Commun. 380, 758–762 (2009).
Traish, A. M., Toselli, P., Jeong, S. J. & Kim, N. N. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiency. J. Androl. 26, 242–248 (2005).
Andric, S. A., Janjic, M. M., Stojkov, N. J. & Kostic, T. S. Testosterone-induced modulation of nitric oxide–cGMP signaling pathway and androgenesis in the rat Leydig cells. Biol. Reprod. 83, 434–442 (2010).
Reilly, C. M., Stopper, V. S. & Mills, T. M. Androgens modulate the α-adrenergic responsiveness of vascular smooth muscle in the corpus cavernosum. J. Androl. 18, 26–31 (1997).
Bancroft, J. & Wu, F. C. Changes in erectile responsiveness during androgen replacement therapy. Arch. Sex. Behav. 12, 59–66 (1983).
Gray, P. B. et al. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J. Clin. Endocrinol. Metab. 90, 3838–3846 (2005).
Buena, F. et al. Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertil. Steril. 59, 1118–1123 (1993).
Kwan, M., Greenleaf, W. J., Mann, J., Crapo, L. & Davidson, J. M. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J. Clin. Endocrinol. Metab. 57, 557–562 (1983).
Giannetta, E., Gianfrilli, D., Barbagallo, F., Isidori, A. M. & Lenzi, A. Subclinical male hypogonadism. Best Pract. Res. Clin. Endocrinol. Metab. 26, 539–550 (2012).
Tajar, A. et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing study. J. Clin. Endocrinol. Metab. 95, 1810–1818 (2010).
Corona, G. et al. Testosterone supplementation and sexual function: a meta-analysis study. J. Sex. Med. 11, 1577–1592 (2014). Meta-analysis that examines the relationship between testosterone therapy and sexual function.
Saad, F. et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur. J. Endocrinol. 165, 675–685 (2011).
Giltay, E. J. et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J. Sex. Med. 7, 2572–2582 (2010).
Hackett, G. et al. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters versus placebo in a population of men with type 2 diabetes. J. Sex. Med. 10, 1612–1627 (2013).
Isidori, A. M. et al. Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J. Endocrinol. Invest. 38, 103–112 (2014).
Basaria, S. et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA 314, 570–581 (2015).
Morgentaler, A. Testosterone, cardiovascular risk, and hormonophobia. J. Sex. Med. 11, 1362–1366 (2014).
Finkle, W. D. et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE 9, e85805 (2014).
Sharma, R. et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur. Heart J. 36, 2706–2715 (2015).
Sansone, A., Romanelli, F., Gianfrilli, D. & Lenzi, A. Endocrine evaluation of erectile dysfunction. Endocrine 46, 423–430 (2014).
Corona, G. et al. Psychobiological correlates of smoking in patients with erectile dysfunction. Int. J. Impot. Res. 17, 527–534 (2005).
Cao, S., Gan, Y., Dong, X., Liu, J. & Lu, Z. Association of quantity and duration of smoking with erectile dysfunction: a dose–response meta-analysis. J. Sex. Med. 11, 2376–2384 (2004).
Boddi, V. et al. Priapus is happier with Venus than with Bacchus. J. Sex. Med. 7, 2831–2841 (2010).
Wang, F., Dai, S., Wang, M. & Morrison, H. Erectile dysfunction and fruit/vegetable consumption among diabetic Canadian men. Urology 82, 1330–1335 (2013).
Cheng, J. Y., Ng, E. M., Ko, J. S. & Chen, R. Y. Physical activity and erectile dysfunction: meta-analysis of population-based studies. Int. J. Impot. Res. 19, 245–252 (2007).
Corona, G. et al. Erectile dysfunction and central obesity: an Italian perspective. Asian J. Androl. 16, 581–591 (2014).
Vignozzi, L. et al. Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit. Mol. Cell. Endocrinol. 384, 143–154 (2014).
Corona, G. et al. The SUBITO-DE study: sexual dysfunction in newly diagnosed type 2 diabetes male patients. J. Endocrinol. Invest. 36, 864–868 (2013).
Corona, G. et al. Sexual dysfunction at the onset of type 2 diabetes: the interplay of depression, hormonal and cardiovascular factors. J. Sex. Med. 11, 2065–2073 (2014).
Corona, G. et al. Hormonal association and sexual dysfunction in patients with impaired fasting glucose: a cross-sectional and longitudinal study. J. Sex. Med. 9, 1669–1680 (2012).
Guo, W. et al. Erectile dysfunction and risk of clinical cardiovascular events: a meta-analysis of seven cohort studies. J. Sex. Med. 7, 2805–2816 (2010).
Dong, J. Y., Zhang, Y. H. & Qin, L. Q. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J. Am. Coll. Cardiol. 58, 1378–1385 (2011).
Vlachopoulos, C. V., Terentes-Printzios, D. G., Ioakeimidis, N. K., Aznaouridis, K. A. & Stefanadis, C. I. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ. Cardiovasc. Qual. Outcomes 6, 99–109 (2013).
Yamada, T., Hara, K., Umematsu, H., Suzuki, R. & Kadowaki, T. Erectile dysfunction and cardiovascular events in diabetic men: a meta-analysis of observational studies. PLoS ONE 7, e4367 (2012).
Nehra, A. et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin. Proc. 87, 766–778 (2012). This manuscript details how erectile dysfunction is an early symptom of cardiovascular disease.
Jannini, E. A., McCabe, M. P., Salonia, A., Montorsi, F. & Sachs, B. D. Organic versus psychogenic? The Manichean diagnosis in sexual medicine. J. Sex. Med. 7, 1726–1733 (2010).
Corona, G. et al. Impairment of couple relationship in male patients with sexual dysfunction is associated with overt hypogonadism. J. Sex. Med. 6, 2591–2600 (2009).
Corona, G. et al. Male sexuality and cardiovascular risk. A cohort study in patients with erectile dysfunction. J. Sex. Med. 7, 1918–1927 (2010).
Althof, S. E., Rosen, R. C., Perelman, M. A. & Rubio-Aurioles, E. Standard operating procedures for taking a sexual history. J. Sex. Med. 10, 26–35 (2013).
Ghanem, H. M., Salonia, A. & Martin-Morales, A. SOP: physical examination and laboratory testing for men with erectile dysfunction. J. Sex. Med. 10, 108–110 (2013).
Buvat, J., Maggi, M., Guay, A. & Torres, L. O. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J. Sex. Med. 10, 245–284 (2013). A detailed review of testosterone deficiency, including current management modalities.
Rastrelli, G. et al. Flaccid penile acceleration as a marker of cardiovascular risk in men without classical risk factors. J. Sex. Med. 11, 173–186 (2014).
Corona, G. et al. Penile doppler ultrasound in patients with erectile dysfunction (ED): role of peak systolic velocity measured in the flaccid state in predicting arteriogenic ED and silent coronary artery disease. J. Sex. Med. 5, 2623–2634 (2008).
Sikka, S. C., Hellstrom, W. J., Brock, G. & Morales, A. M. Standardization of vascular assessment of erectile dysfunction: standard operating procedures for duplex ultrasound. J. Sex. Med. 10, 120–129 (2013).
Maiorino, M. I., Bellastella, G. & Esposito, K. Lifestyle modifications and erectile dysfunction: what can be expected? Asian J. Androl. 17, 5–10 (2015).
Esposito, K. et al. Dietary factors in erectile dysfunction. Int. J. Impot. Res. 18, 370–374 (2006).
Hannan, J. L., Heaton, J. P. W. & Adams, M. A. Recovery of erectile function in aging hypertensive and normotensive rats using exercise and caloric restriction. J. Sex. Med. 4, 886–897 (2007).
Kolotkin, R. L. et al. Improvements in sexual quality of life after moderate weight loss. Int. J. Impot. Res. 20, 487–492 (2008).
Belardinelli, R., Lacalaprice, F., Faccenda, E., Purcaro, A. & Perna, G. Effects of short-term moderate exercise training on sexual function in male patients with chronic stable heart failure. Int. J. Cardiol. 101, 83–90 (2005).
Kupelian, V., Link, C. L. & McKinlay, J. B. Association between smoking, passive smoking, and erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. Eur. Urol. 52, 416–422 (2007).
Polsky, J. Y., Aronson, K. J., Heaton, J. P. & Adams, M. A. Smoking and other lifestyle factors in relation to erectile dysfunction. BJU Int. 96, 1355–1359 (2005).
Pourmand, G., Alidaee, M. R., Rasuli, S., Maleki, A. & Mehrsai, A. Do cigarette smokers with erectile dysfunction benefit from stopping?: a prospective study. BJU Int. 94, 1310–1313 (2004).
Chew, K. K. Alcohol consumption and male erectile dysfunction: an unfounded reputation for risk? J. Sex. Med. 6, 2340–2340 (2009).
Arackal, B. S. & Benegal, V. Prevalence of sexual dysfunction in male subjects with alcohol dependence. Indian J. Psychiatry 49, 109–112 (2007).
Aghighi, A., Grigoryan, V. H. & Delavar, A. Psychological determinants of erectile dysfunction among middle-aged men. Int. J. Impot. Res. 27, 63–68 (2014).
Schmidt, H. M., Munder, T., Gerger, H., Fruhauf, S. & Barth, J. Combination of psychological intervention and phosphodiesterase-5 inhibitors for erectile dysfunction: a narrative review and meta-analysis. J. Sex. Med. 11, 1376–1391 (2014).
Hatzimouratidis, K. et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur. Urol. 57, 804–814 (2010).
Goldstein, I. et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N. Engl. J. Med. 338, 1397–1404 (1998). This seminal paper was the first time that sildenafil was used as treatment for erectile dysfunction.
Yuan, J. et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur. Urol. 63, 902–912 (2013).
Corbin, J. D. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int. J. Impot. Res. 16, S4–S7 (2004).
Nichols, D. J., Muirhead, G. J. & Harness, J. A. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br. J. Clin. Pharmacol. 53, S5–S12 (2002).
Curran, M. & Keating, G. Tadalafil. Drugs 63, 2203–2212; discussion 2213–2214 (2003).
Jung, J. et al. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. Clin. Ther. 32, 1178–1187 (2010).
Porst, H. et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J. Sex. Med. 10, 130–171 (2013).
Stuckey, B. G. et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 26, 279–284 (2003).
Boulton, A. J., Selam, J. L., Sweeney, M. & Ziegler, D. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 44, 1296–1301 (2001).
Shabsigh, R. Testosterone therapy in erectile dysfunction and hypogonadism. J. Sex. Med. 2, 785–792 (2005).
Padma-Nathan, H. et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int. J. Impot. Res. 20, 479–486 (2008).
Zelefsky, M. J. et al. Prophylactic sildenafil citrate improves select aspects of sexual function in men treated with radiotherapy for prostate cancer. J. Urol. 192, 868–874 (2014). This manuscript shows the benefit of sidenafil in decreasing the incidence of erectile dysfunction in patients undergoing radiotherapy for prostate cancer.
Corona, G., Razzoli, E., Forti, G. & Maggi, M. The use of phosphodiesterase 5 inhibitors with concomitant medications. J. Endocrinol. Invest. 31, 799–808 (2008).
Giuliano, F., Jackson, G., Montorsi, F., Martin-Morales, A. & Raillard, P. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int. J. Clin. Pract. 64, 240–255 (2010).
Bosshardt, R. J., Farwerk, R., Sikora, R., Sohn, M. & Jakse, G. Objective measurement of the effectiveness, therapeutic success and dynamic mechanisms of the vacuum device. Br. J. Urol. 75, 786–791 (1995).
Price, D. E. et al. The management of impotence in diabetic men by vacuum tumescence therapy. Diabet. Med. 8, 964–967 (1991).
Levine, L. A. & Dimitriou, R. J. Vacuum constriction and external erection devices in erectile dysfunction. Urol. Clin. North Am. 28, 335–341 (2001).
Baltaci, S., Aydos, K., Kosar, A. & Anafarta, K. Treating erectile dysfunction with a vacuum tumescence device: a retrospective analysis of acceptance and satisfaction. Br. J. Urol. 76, 757–760 (1995).
Ganem, J. P., Lucey, D. T., Janosko, E. O. & Carson, C. C. Unusual complications of the vacuum erection device. Urology 51, 627–631 (1998).
Raina, R. et al. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int. J. Impot. Res. 18, 77–81 (2006).
Moreland, R. B., Kim, N., Nehra, A., Goldstein, I. & Traish, A. Functional prostaglandin E (EP) receptors in human penile corpus cavernosum. Int. J. Impot. Res. 15, 362–368 (2003).
Padma-Nathan, H. et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N. Engl. J. Med. 336, 1–7 (1997).
Williams, G. et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. Br. J. Urol. 81, 889–894 (1998).
McCullough, A. R. et al. Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethralalprostadil versus sildenafil citrate. J. Urol. 183, 2451–2456 (2010).
Guay, A. T., Perez, J. B., Velasquez, E., Newton, R. A. & Jacobson, J. P. Clinical experience with intraurethralalprostadil (MUSE) in the treatment of men with erectile dysfunction. A retrospective study. Medicated urethral system for erection. Eur. Urol. 38, 671–676 (2000).
Costabile, R. A. et al. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J. Urol. 160, 1325–1328 (1998).
Virag, R., Shoukry, K., Floresco, J., Nollet, F. & Greco, E. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J. Urol. 145, 287–292; discussion 292–293 (1991).
Nelson, C. J. et al. Injection anxiety and pain in men using intracavernosal injection therapy after radical pelvic surgery. J. Sex. Med. 10, 2559–2565 (2013).
Heaton, J. P. et al. Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int. J. Impot. Res. 13, 317–321 (2001).
Althof, S. E. et al. Why do so many people drop out from auto-injection therapy for impotence? J. Sex. Marital Ther. 15, 121–129 (1989).
Weiss, J. N., Badlani, G. H., Ravalli, R. & Brettschneider, N. Reasons for high drop-out rate with self-injection therapy for impotence. Int. J. Impot. Res. 6, 171–174 (1994).
Mulhall, J. P. et al. The causes of patient dropout from penile self-injection therapy for impotence. J. Urol. 162, 1291–1294 (1999).
Linet, O. I. & Ogrinc, F. G. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N. Engl. J. Med. 334, 873–877 (1996).
Tal, R., Teloken, P. & Mulhall, J. P. Erectile function rehabilitation after radical prostatectomy: practice patterns among AUA members. J. Sex. Med. 8, 2370–2376 (2011).
Trost, L. W., McCaslin, R., Linder, B. & Hellstrom, W. J. Long-term outcomes of penile prostheses for the treatment of erectile dysfunction. Expert Rev. Med. Devices 10, 353–366 (2013).
Zermann, D. H., Kutzenberger, J., Sauerwein, D., Schubert, J. & Loeffler, U. Penile prosthetic surgery in neurologically impaired patients: long-term follow-up. J. Urol. 175, 1041–1044 (2006).
Levine, L. A., Estrada, C. R. & Morgentaler, A. Mechanical reliability and safety of, and patient satisfaction with the Ambicor inflatable penile prosthesis: results of a 2 center study. J. Urol. 166, 932–937 (2001).
Levine, L. A. & Lenting, E. A surgical algorithm for the treatment of Peyronie's disease. J. Urol. 158, 2149–2152 (1997).
Montorsi, F., Guazzoni, G., Bergamaschi, F. & Rigatti, P. Patient–partner satisfaction with semirigid penile prostheses for Peyronie's disease: a 5-year follow-up study. J. Urol. 150, 1819–1821 (1993).
Wilson, S. K. & Delk, J. R. 2nd. A new treatment for Peyronie's disease: modeling the penis over an inflatable penile prosthesis. J. Urol. 152, 1121–1123 (1994). This manuscript describes a technique used to correct Peyronie's disease and erectile dysfunction in the same procedure.
Martínez-Salamanca, J. I., Mueller, A., Moncada, I., Carballido, J. & Mulhall, J. P. Penile prosthesis surgery in patients with corporal fibrosis: a state of the art review. J. Sex. Med. 8, 1880–1889 (2011).
Dhar, N. B., Angermeir, K. W. & Montague, D. K. Long-term mechanical reliability of AMS 700CX/CXM inflatable penile prosthesis. J. Urol. 176, 2599–2601 (2006).
Hellstrom, W. J. et al. Implants, mechanical devices, and vascular surgery for erectile dysfunction. J. Sex. Med. 7, 501–523 (2010).
Trost, L. W., Baum, N. & Hellstrom, W. J. Managing the difficult penile prosthesis patient. J. Sex. Med. 10, 893–906 (2013).
Rajpurkar, A. & Dhabuwala, C. B. Comparison of satisfaction rates and erectile function in patients treated with sildenafil, intracavernous prostaglandin E1 and penile implant surgery for erectile dysfunction in urology practice. J. Urol. 170, 159–163 (2003).
Vardi, Y. et al. Evaluation of penile revascularization for erectile dysfunction: a 10-year follow-up. Int. J. Impot. Res. 16, 181–186 (2004).
Wespes, E., Wildschutz, T., Roumeguere, T. & Schulman, C. C. The place of surgery for vascular impotence in the third millennium. J. Urol. 170, 1284–1286 (2003).
Manning, M. et al. Long-term follow up and selection criteria for penile revascularization in erectile failure. J. Urol. 160, 1680–1684 (1998).
Sohn, M. & Martin-Morales, A. Surgical Treatment of Erectile Dysfunction (Porst JB, 2006).
Montague, D. K. et al. Chapter 1: the management of erectile dysfunction: an AUA update. J. Urol. 174, 230–239 (2005).
Araujo, A. B., Durante, R., Feldman, H. A., Goldstein, I. & McKinlay, J. B. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom. Med. 60, 458–465 (1998). This is an important study, as it helps to define the relationship between erectile dysfunction and depression. The MMAS provides population-based data that demonstrate sound evidence for this relationship.
Nelson, C. J., Mulhall, J. P. & Roth, A. J. The association between erectile dysfunction and depressive symptoms in men treated for prostate cancer. J. Sex. Med. 8, 560–566 (2011).
Shabsigh, R. et al. Increased incidence of depressive symptoms in men with erectile dysfunction. Urology 52, 848–852 (1998).
Shiri, R. et al. Bidirectional relationship between depression and erectile dysfunction. J. Urol. 177, 669–673 (2007).
Mallis, D. et al. Psychiatric morbidity is frequently undetected in patients with erectile dysfunction. J. Urol. 174, 1913–1916 (2005).
Hedon, F. Anxiety and erectile dysfunction: a global approach to ED enhances results and quality of life. Int. J. Impot. Res. 15, S16–S19 (2003).
Hale, V. E. & Strassberg, D. S. The role of anxiety on sexual arousal. Arch. Sex. Behav. 19, 569–581 (1990).
Beck, J. G. & Barlow, D. H. The effects of anxiety and attentional focus on sexual responding — II: cognitive and affective patterns in erectile dysfunction. Behav. Res. Ther. 24, 19–26 (1986).
de Boer, B. J., Bots, M. L., Nijeholt, A. A., Moors, J. P. & Verheij, T. J. The prevalence of bother, acceptance, and need for help in men with erectile dysfunction. J. Sex. Med. 2, 445–450 (2005).
Nelson, C. J. et al. Men's experience with penile rehabilitation following radical prostatectomy: a qualitative study with the goal of informing a therapeutic intervention. Psychooncology 24, 1646–1654 (2015).
Schover, L. R. et al. Defining sexual outcomes after treatment for localized prostate carcinoma. Cancer 95, 1773–1785 (2002).
Sundaram, C. P. et al. Long-term follow-up of patients receiving injection therapy for erectile dysfunction. Urology 49, 932–935 (1997).
Huang, S. A. & Lie, J. D. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. P T 38, 407–419 (2013).
Jiann, B. P., Yu, C. C. & Tsai, J. Y. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int. J. Impot. Res. 18, 146–149 (2006).
Klotz, T., Mathers, M., Klotz, R. & Sommer, F. Why do patients with erectile dysfunction abandon effective therapy with sildenafil (Viagra)? Int. J. Impot. Res. 17, 2–4 (2005).
Lindau, S., Laumann, E., Levinson, W. & Waite, L. Synthesis of scientific disciplines in pursuit of health: the Interactive Biopsychosocial Model. Perspect. Biol. Med. 46, S74–S86 (2003).
Goldfarb, S., Baron, S. & Lindau, S. in Women and Health (eds Goldman, M. B., Troisi, R. & Rexrode, K. M. ) 347–357 (Academic Press, 2013).
Lindau, S., Sandbo, S., Goldfarb, S. & Dickler, M. in Cancer and Sexual Health (eds Mulhall, J. P., Goldstein, I., Incrocci, L & Rosen, R. ) 415–455 (Springer, 2011).
Fisher, W., Rosen, R., Eardley, I., Sand, M. & Goldstein, I. Sexual experience of female partners of men with erectile dysfunction: the female experience of men's attitudes to life events and sexuality (FEMALES) study. J. Sex. Med. 2, 675–684 (2005). An important study that furthers our understanding of how erectile dysfunction can affect a couple's relationship and helps to define possible strategies that a couple could use to cope with the emotional strain caused by erectile dysfunction.
Jiann, B. P., Su, C. C. & Tsai, J. Y. Is female sexual function related to the male partners' erectile function? J. Sex. Med. 10, 420–429 (2013).
Fisher, W. A. et al. Improving the sexual quality of life of couples affected by erectile dysfunction: a double-blind, randomized, placebo-controlled trial of vardenafil. J. Sex. Med. 2, 699–708 (2005).
Goldstein, I. et al. Women's sexual function improves when partners are administered vardenafil for erectile dysfunction: a prospective, randomized, double-blind, placebo-controlled trial. J. Sex. Med. 2, 819–832 (2005). This manuscript describes the benefits to their female partner when erectile dysfunction is treated in their partner.
Tran, S. N. et al. Prospective evaluation of early postoperative male and female sexual function after radical prostatectomy with erectile nerves preservation. Int. J. Impot. Res. 27, 69–74 (2015).
Albersen, M., Shindel, A. W., Mwamukonda, K. B. & Lue, T. F. The future is today: emerging drugs for the treatment of erectile dysfunction. Expert Opin. Emerg. Drugs 15, 467–480 (2010).
Hakim, L., Van der Aa, F., Bivalacqua, T. J., Hedlund, P. & Albersen, M. Emerging tools for erectile dysfunction: a role for regenerative medicine. Nat. Rev. Urol. 9, 520–536 (2012).
Hatzimouratidis, K. & Hatzichristou, D. Phosphodiesterase type 5 inhibitors: the day after. Eur. Urol. 51, 75–88; discussion 89 (2007).
Burnett, A. L. et al. Future sexual medicine physiological treatment targets. J. Sex. Med. 7, 3269–3304 (2010). A good review summarizing future prospects being researched in the treatment of erectile dysfunction.
Chitaley, K. et al. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat. Med. 7, 119–122 (2001).
Gratzke, C. et al. Activated RhoA/Rho kinase impairs erectile function after cavernous nerve injury in rats. J. Urol. 184, 2197–2204 (2010).
Bivalacqua, T. J. et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc. Natl Acad. Sci. USA 101, 9121–9126 (2004).
Jin, L. et al. Elevated RhoA/Rho-kinase activity in the aged rat penis: mechanism for age-associated erectile dysfunction. FASEB J. 20, 536–538 (2006).
Albersen, M. et al. Increased Rho-kinase 2 and an increase of synthetic smooth muscle-specific marker expression is observed in the corpus cavernosum of patients with severe erectile dysfunction. J. Urol. 191, e526 (2014).
Oudot, A. et al. Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. Eur. Urol. 60, 1020–1026 (2011).
Albersen, M., Linsen, L., Tinel, H., Sandner, P. & Van Renterghem, K. Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. J. Sex. Med. 10, 1268–1277 (2013).
US National Library of Science. Multiple dose escalation study (14 days) to investigate safety, tolerability, PK and PD of vardenafil and BAY60-4552. ClinicalTrials.gov [online],https://clinicaltrials.gov/ct2/show/NCT01110590(2010).
US National Library of Science. Clinical proof-of-concept study for the combination BAY60-4552 / vardenafil for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitors. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01168817?term=NCT01168817&rank=1 (2010).
Melman, A., Bar-Chama, N., McCullough, A., Davies, K. & Christ, G. The first human trial for gene transfer therapy for the treatment of erectile dysfunction: preliminary results. Eur. Urol. 48, 314–318 (2005). This manuscript describes the first human trial of gene transfer therapy for erectile dysfunction treatment.
Albersen, M., Weyne, E. & Bivalacqua, T. J. Stem cell therapy for erectile dysfunction: progress and future directions. Sex. Med. Rev. 1, 50–64 (2013). This manuscript discusses the current status and future outlook of stem cell therapy for erectile dysfunction treatment.
Lin, G. et al. Potential of adipose-derived stem cells for treatment of erectile dysfunction. J. Sex. Med. 6 (Suppl. 3), 320–327 (2009).
Bahk, J. Y., Jung, J. H., Han, H., Min, S. K. & Lee, Y. S. Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Exp Clin. Transplant. 8, 150–160 (2010).
Yiou, R. et al. Safety of intracavernous bone marrow-mononuclear cells for postradical prostatectomy erectile dysfunction: an open dose-escalation pilot study. Eur Urol. http://dx.doi.org/10.1016/j.eururo.2015.09.026 (2015).
US National Library of Science. Evaluate the use of liposuction and cell separation devices for autologous fat (adipose) derived cells to treat the symptoms of erectile dysfunction. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01601353 (2015).
US National Library of Science. Allogeneic human bone marrow derived mesenchymal stem cells in localized prostate cancer (MSC). ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01983709 (2015).
US National Library of Science. Autologous adipose-derived stromal cells delivered into the corpus cavernous in patients with erectile dysfunction. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02087397 (2014).
US National Library of Science. Can fat derived stem cells (SVF) be used in the treatment of erectile dysfunction after prostatectomy. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02240823 (2015).
US National Library of Science. Safety of autologous bone marrow derived mesenchymal stem cells in erectile dysfunction. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02344849 (2015).
US National Library of Science. Evaluate the safety and feasibility of injecting PMD-MSC into the penis to treat the symptoms of mild to moderate ED (PMD-MSC-ED-01). ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT02398370 (2015).
US National Library of Science. Safety and clinical outcomes study: SVF deployment for orthopedic, neurologic, urologic, and cardio-pulmonary conditions. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01953523 (2015).
Michal, V. Vascular surgery in the treatment of imporence; its present possibilities and prospects. Czech Med. 3, 213–217 (1980).
Brindley, G. S. Cavernosal α-blockade: a new technique for investigating and treating erectile impotence. Br. J. Psychiaty 143, 332–337 (1983).
Campeau, L. Grading of angina pectoria. Circulation 54, 522–523 (1976).
M.A. has received grants from Ferring, Bayer, ESSM and ISSM, and served as an advisor for Sandoz, Sobi and Sanofi. G.C. has received consultancy fees from Bayer, Besins, Otsuka, Eli-Lilly and Menarini. A.M.I. has served as an advisor for Otsuka, Shire, Besins, Novartis and Menarini. M.M. has served as an advisor and/or received speaker's fees from Bayer, Ely Lilly, Menarini, Prostrakan and Intercept. C.J.N. has served as an unpaid advisor for American Medical Systems. S.P. has served as an advisor for Pfizer, Sprout Pharmaceuticals, Emotional Brain and Strategic Science Technologies, and received speaker's fees from Pfizer. R.T. has served as an advisor for Lilly and Orient Europharma, and received speaker's fees from Lilly. J.P.M. has received grants from CIACT, NIH and SMSNA, and served as an advisor for Lilly, Pfizer and AMS. W.J.G.H. has served as an advisor for Abbvie, American Medical Systems, Coloplast and Pfizer. The other authors declare no competing interests.
PowerPoint slide for Fig. 1
PowerPoint slide for Fig. 2
PowerPoint slide for Fig. 3
PowerPoint slide for Fig. 4
PowerPoint slide for Fig. 5
PowerPoint slide for Fig. 6
PowerPoint slide for Fig. 7
PowerPoint slide for Fig. 8
PowerPoint slide for Fig. 9
About this article
Cite this article
Yafi, F., Jenkins, L., Albersen, M. et al. Erectile dysfunction. Nat Rev Dis Primers 2, 16003 (2016). https://doi.org/10.1038/nrdp.2016.3
Erectile Dysfunction Is Associated With Excessive Growth Hormone Levels in Male Patients With Acromegaly
Frontiers in Endocrinology (2021)
An Analysis of a Commercial Database on the Use of Erectile Dysfunction Treatments for Men With Employer-Sponsored Health Insurance
Sexual Medicine Reviews (2021)
The American Journal of Medicine (2021)
Comparative effect of administration and discontinuation of sildenafil and/or clomipramine on the hepatic, cardiac and testicular tissues of male rats